Li-Yuan Bai

16PUBLICATIONS
143CO-AUTHORS
Molecular targetsPredictive and prognostic markersChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Nutrigenomics and personalised nutrition
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 02, 2026
Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

|Jun 25, 2026
Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

|Jun 01, 2026
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.

|Dec 10, 2025
Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer.

Hsiu-Tzu Wang, Yung-Luen Yu, Wen-Jyi Lo

|Dec 01, 2025
Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma.

Keun-Wook Lee, Li-Yuan Bai, Minkyu Jung

|Oct 21, 2025
Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial.

Muh-Hwa Yang, Shang-Yin Wu, I-Wei Ho

Pageof 3

Frequent Collaborators

4 joint publications

Keun-Wook Lee

4 joint publications

Li-Tzong Chen

3 joint publications

Jen-Shi Chen

3 joint publications

Kohei Shitara